Indeed, co-administration of TLR agonists in protein and peptide based cancer vaccines have entered clinical phase such as the TLR3 ligand poly ICLC (Hiltonol®) demonstrating tumor regression of advanced facial rhabdomyosarcoma (136), or the TLR7 agonist Imiquimod which has been approved for treatment of basal cell carcinoma due to its ability of CTL-mediated tumor regression by DC and NK cell recruitment (137). This evidence concerns the gene TLR7 and neoplasm.